Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Elevated Serum Levels of Ischemia Modified Albumin and Malondialdehyde are Related to Atherogenic Index of Plasma in a Cohort of Prediabetes

Author(s): Mervat M. El-Eshmawy*, Doaa F. Gad and Azza A. El-Baiomy

Volume 20, Issue 8, 2020

Page: [1347 - 1354] Pages: 8

DOI: 10.2174/1871530320666200503052226

Price: $65

Abstract

Background: Prediabetes, defined as impaired glucose tolerance and/or impaired fasting glucose, is a risk factor for future type 2 diabetes, dyslipidemia, cardiovascular disease and all-cause mortality. High serum levels of ischemia modified albumin (IMA) and malondialdehyde (MDA) as oxidative stress markers were determined in diabetes, however, no studies have investigated these markers together in prediabetes. The aim of the present study was to investigate the circulating levels of both IMA and MDA in a cohort of prediabetic adults. The possible associations between both markers and the atherogenic index of plasma (AIP) were also evaluated.

Methods: This study enrolled 100 adults with prediabetes and 50 healthy controls matched for age and sex. Anthropometric measurements, fasting and 2-hour post load glucose, glycosylated hemoglobin (A1c), lipids profile, fasting insulin, homeostasis model assessment of insulin resistance (HOMA-IR), high sensitivity C-reactive protein (hs-CRP), AIP, IMA and MDA were assessed.

Results: IMA, MDA, hs-CRP and AIP were significantly higher in adults with prediabetes than in healthy controls. Male gender, fasting and post load glucose, A1c, fasting insulin, TGs, HDL-C, hs- CRP, AIP and MDA were independent predictor variables of IMA, whereas male gender, WC, fasting and post load glucose, A1c, fasting insulin, TC, TGs, LDL-C, HDL-C, hs-CRP and AIP were independent predictor variables of MDA.

Conclusion: The elevation of IMA concomitantly with MDA reflecting the antioxidant status in prediabetes, and their associations with hs-CRP and AIP should reinforce the idea of screening and treatment of prediabetes.

Keywords: Oxidative stress, ischemia modified albumin, malondialdehyde, atherogenic index of plasma, high sensitivity Creactive protein, prediabetes.

« Previous Next »
Graphical Abstract

[1]
Sies, H. Biochemistry of oxidative stress. Angew. Chem. Int. Ed. Engl., 1986, 25(12), 1058-1071.
[http://dx.doi.org/10.1002/anie.198610581]
[2]
Vachharajani, V.; Granger, D.N. Adipose tissue: a motor for the inflammation associated with obesity. IUBMB Life, 2009, 61(4), 424-430.
[http://dx.doi.org/10.1002/iub.169] [PMID: 19319966]
[3]
Olusi, S.O. Obesity is an independent risk factor for plasma lipid peroxidation and depletion of erythrocyte cytoprotectic enzymes in humans. Int. J. Obes. Relat. Metab. Disord., 2002, 26(9), 1159-1164.
[http://dx.doi.org/10.1038/sj.ijo.0802066] [PMID: 12187391]
[4]
Hunt, J.V.; Smith, C.C.; Wolff, S.P. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes, 1990, 39(11), 1420-1424.
[http://dx.doi.org/10.2337/diab.39.11.1420] [PMID: 2227114]
[5]
Su, Y.; Liu, X.M.; Sun, Y.M.; Jin, H.B.; Fu, R.; Wang, Y.Y.; Wu, Y.; Luan, Y. The relationship between endothelial dysfunction and oxidative stress in diabetes and prediabetes. Int. J. Clin. Pract., 2008, 62(6), 877-882.
[http://dx.doi.org/10.1111/j.1742-1241.2008.01776.x] [PMID: 18479281]
[6]
Weyer, C.; Bogardus, C.; Mott, D.M.; Pratley, R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J. Clin. Invest., 1999, 104(6), 787-794.
[http://dx.doi.org/10.1172/JCI7231] [PMID: 10491414]
[7]
Kaneto, H.; Katakami, N.; Kawamori, D.; Miyatsuka, T.; Sakamoto, K.; Matsuoka, T.A.; Matsuhisa, M.; Yamasaki, Y. Involvement of oxidative stress in the pathogenesis of diabetes. Antioxid. Redox Signal., 2007, 9(3), 355-366.
[http://dx.doi.org/10.1089/ars.2006.1465] [PMID: 17184181]
[8]
World Health Organization International Diabetes Federation. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia: Report of a WHO/IDF consultation; World Health Organization: Geneva, 2006.
[9]
Anonymous, Standards of Medical Care in Diabetes—2008. American Diabetes Association. Diabetes Care, 2008, 31(Suppl. 1), S12.
[http://dx.doi.org/10.2337/dc08-S012]
[10]
Huang, Y.; Cai, X.; Mai, W.; Li, M.; Hu, Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ, 2016, 355, i5953.
[http://dx.doi.org/10.1136/bmj.i5953] [PMID: 27881363]
[11]
Mehmetoğlu, I.; Kurban, S.; Yerlikaya, F.H.; Polat, H. Obesity is an independent determinant of ischemia-modified albumin. Obes. Facts, 2012, 5(5), 700-709.
[http://dx.doi.org/10.1159/000343954] [PMID: 23108391]
[12]
da Silva, S.H. Hausen, Bdos.S.; da Silva, D.B.; Becker, A.M.; de Campos, M.M.; Duarte, M.M.; Moresco, R.N. Characteristics of a nickel-albumin binding assay for assessment of myocardial ischaemia. Biomarkers, 2010, 15(4), 353-357.
[http://dx.doi.org/10.3109/13547501003763369] [PMID: 20384453]
[13]
Roy, D.; Quiles, J.; Gaze, D.C.; Collinson, P.; Kaski, J.C.; Baxter, G.F. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart, 2006, 92(1), 113-114.
[http://dx.doi.org/10.1136/hrt.2004.049643] [PMID: 16365361]
[14]
Kotur-Stevuljevic, J.; Memon, L.; Stefanovic, A.; Spasic, S.; Spasojevic-Kalimanovska, V.; Bogavac-Stanojevic, N.; Kalimanovska-Ostric, D.; Jelić-Ivanovic, Z.; Zunic, G. Correlation of oxidative stress parameters and inflammatory markers in coronary artery disease patients. Clin. Biochem., 2007, 40(3-4), 181-187.
[http://dx.doi.org/10.1016/j.clinbiochem.2006.09.007] [PMID: 17070511]
[15]
Vassalle, C.; Pratali, L.; Boni, C.; Mercuri, A.; Ndreu, R. An oxidative stress score as a combined measure of the pro-oxidant and anti-oxidant counterparts in patients with coronary artery disease. Clin. Biochem., 2008, 41(14-15), 1162-1167.
[http://dx.doi.org/10.1016/j.clinbiochem.2008.07.005] [PMID: 18692492]
[16]
Sbarouni, E.; Georgiadou, P.; Kremastinos, D.T.; Voudris, V. Ischemia modified albumin: is this marker of ischemia ready for prime time use? Hellenic J. Cardiol., 2008, 49(4), 260-266.
[PMID: 18935713]
[17]
Dash, P.; Mangaraj, M.; Ray, S. Physiobiochemical metabolism ischaemia modified albumin-an indicator of widespread endothelial damage in diabetes. J. Physiobiochem. Metab., 2014, 3, 1.
[18]
Esterbauer, H.; Schaur, R.J.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med., 1991, 11(1), 81-128.
[http://dx.doi.org/10.1016/0891-5849(91)90192-6] [PMID: 1937131]
[19]
Wang, R.H.; Kim, H.S.; Xiao, C.; Xu, X.; Gavrilova, O.; Deng, C.X. Hepatic Sirt1 deficiency in mice impairs mTorc2/Akt signaling and results in hyperglycemia, oxidative damage, and insulin resistance. J. Clin. Invest., 2011, 121(11), 4477-4490.
[http://dx.doi.org/10.1172/JCI46243] [PMID: 21965330]
[20]
Kaefer, M.; De Carvalho, J.A.; Piva, S.J.; da Silva, D.B.; Becker, A.M.; Sangoi, M.B.; Almeida, T.C.; Hermes, C.L.; Coelho, A.C.; Tonello, R.; Moreira, A.P.; Garcia, S.C.; Moretto, M.B.; Moresco, R.N. Plasma malondialdehyde levels and risk factors for the development of chronic complications in type 2 diabetic patients on insulin therapy. Clin. Lab., 2012, 58(9-10), 973-978.
[PMID: 23163113]
[21]
Jiménez-Osorio, A.S.; Picazo, A.; González-Reyes, S.; Barrera-Oviedo, D.; Rodríguez-Arellano, M.E.; Pedraza-Chaverri, J. Nrf2 and redox status in prediabetic and diabetic patients. Int. J. Mol. Sci., 2014, 15(11), 20290-20305.
[http://dx.doi.org/10.3390/ijms151120290] [PMID: 25383674]
[22]
Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28(7), 412-419.
[http://dx.doi.org/10.1007/BF00280883] [PMID: 3899825]
[23]
Friedewald, W.T.; Levy, R.I.; Fredrickson, D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem., 1972, 18(6), 499-502.
[http://dx.doi.org/10.1093/clinchem/18.6.499] [PMID: 4337382]
[24]
Dobiásová, M.; Frohlich, J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)). Clin. Biochem., 2001, 34(7), 583-588.
[http://dx.doi.org/10.1016/S0009-9120(01)00263-6] [PMID: 11738396]
[25]
Ukinc, K.; Eminagaoglu, S.; Ersoz, H.O.; Erem, C.; Karahan, C.; Hacihasanoglu, A.B.; Kocak, M. A novel indicator of widespread endothelial damage and ischemia in diabetic patients: ischemia-modified albumin. Endocrine, 2009, 36(3), 425-432.
[http://dx.doi.org/10.1007/s12020-009-9236-5] [PMID: 19784800]
[26]
Kaefer, M.; Piva, S.J.; De Carvalho, J.A.; Da Silva, D.B.; Becker, A.M.; Coelho, A.C.; Duarte, M.M.; Moresco, R.N. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin. Biochem., 2010, 43(4-5), 450-454.
[http://dx.doi.org/10.1016/j.clinbiochem.2009.11.018] [PMID: 19968982]
[27]
Guerin-Dubourg, A.; Cournot, M.; Planesse, C.; Debussche, X.; Meilhac, O.; Rondeau, P.; Bourdon, E. Association between fluorescent advanced glycation end-products and vascular complications in type 2 diabetic patients. BioMed Res. Int., 2017. 20177989180
[http://dx.doi.org/10.1155/2017/7989180] [PMID: 29362717]
[28]
Piwowar, A.; Knapik-Kordecka, M.; Warwas, M. Ischemia-modified albumin level in type 2 diabetes mellitus - Preliminary report. Dis. Markers, 2008, 24(6), 311-317.
[http://dx.doi.org/10.1155/2008/784313] [PMID: 18688079]
[29]
Turk, A.; Nuhoglu, I.; Mentese, A.; Karahan, S.C.; Erdol, H.; Erem, C. The relationship between diabetic retinopathy and serum levels of ischemia-modified albumin and malondialdehyde. Retina, 2011, 31(3), 602-608.
[http://dx.doi.org/10.1097/IAE.0b013e3181ed8cd1] [PMID: 21273947]
[30]
Katakami, N.; Kaneto, H.; Shimomura, I. Carotid ultrasonography: A potent tool for better clinical practice in diagnosis of atherosclerosis in diabetic patients. J. Diabetes Investig., 2014, 5(1), 3-13.
[http://dx.doi.org/10.1111/jdi.12106] [PMID: 24843729]
[31]
Chawla, R.; Loomba, R.; Guru, D.; Loomba, V. Ischemia modified albumin (IMA) - A marker of glycaemic control and vascular complications in Type 2 diabetes mellitus. J. Clin. Diagn. Res., 2016, 10(3), BC13-BC16.
[http://dx.doi.org/10.7860/JCDR/2016/15282.7432] [PMID: 27134857]
[32]
Inal, Z.O.; Erdem, S.; Gederet, Y.; Duran, C.; Kucukaydin, Z.; Kurku, H.; Sakarya, D.K. The impact of serum adropin and ischemia modified albumin levels based on BMI in PCOS. Endokrynol. Pol., 2018, 69(2), 135-141.
[PMID: 29465156]
[33]
Refaat, S. Abd EL-Ghaffar N, Khalil A. The Relationship between Ischemia Modified albumin and lipids in type 2 egyptian diabetic patients. Adv. Biol. Res. (Faisalabad), 2014, 8, 18-22.
[34]
D’Souza, J.M.; D’Souza, R.P.; Vijin, V.F.; Shetty, A.; Arunachalam, C.; Pai, V.R.; Shetty, R.; Faarisa, A. High predictive ability of glycated hemoglobin on comparison with oxidative stress markers in assessment of chronic vascular complications in type 2 diabetes mellitus. Scand. J. Clin. Lab. Invest., 2016, 76(1), 51-57.
[http://dx.doi.org/10.3109/00365513.2015.1092048] [PMID: 26494020]
[35]
Dzięgielewska-Gęsiak, S.; Wysocka, E.; Michalak, S.; Nowakowska-Zajdel, E.; Kokot, T.; Muc-Wierzgoń, M. Role of lipid peroxidation products, plasma total antioxidant status, and Cu-, Zn-superoxide dismutase activity as biomarkers of oxidative stress in elderly prediabetics. Oxid. Med. Cell. Longev., 2014. 2014987303
[http://dx.doi.org/10.1155/2014/987303] [PMID: 24891926]
[36]
Moreto, F.; de Oliveira, E.P.; Manda, R.M.; Burini, R.C. The higher plasma malondialdehyde concentrations are determined by metabolic syndrome-related glucolipotoxicity. Oxid. Med. Cell. Longev., 2014. 2014505368
[http://dx.doi.org/10.1155/2014/505368] [PMID: 25089170]
[37]
Morsi, H.K.; Ismail, M.M.; Gaber, H.A.; Elbasmy, A.A. Macrophage migration inhibitory factor and malondialdehyde as potential predictors of vascular risk complications in type 2 diabetes mellitus: Cross-sectional case control study in Saudi Arabia. Mediators Inflamm., 2016. 20165797930
[http://dx.doi.org/10.1155/2016/5797930] [PMID: 27298517]
[38]
Rkhaya, S.A.; Bulatova, N.; Kasabri, V.; Naffa, R.; Alquoqa, R. Increased malondialdehyde vs. reduced sirtuin 1 in relation with adiposity, atherogenicity and hematological indices in metabolic syndrome patients with and without prediabetes. Diabetes Metab. Syndr., 2018, 12(6), 903-909.
[http://dx.doi.org/10.1016/j.dsx.2018.05.013] [PMID: 29779969]
[39]
Maschirow, L.; Khalaf, K.; Al-Aubaidy, H.A.; Jelinek, H.F. Inflammation, coagulation, endothelial dysfunction and oxidative stress in prediabetes--Biomarkers as a possible tool for early disease detection for rural screening. Clin. Biochem., 2015, 48(9), 581-585.
[http://dx.doi.org/10.1016/j.clinbiochem.2015.02.015] [PMID: 25753569]
[40]
Agarwal, A.; Hegde, A.; Yadav, C.; Ahmad, A.; Manjrekar, P.A.; Srikantiah, R.M. Assessment of oxidative stress and inflammation in prediabetes-A hospital based cross-sectional study. Diabetes Metab. Syndr., 2016, 10(2)(Suppl. 1), S123-S126.
[http://dx.doi.org/10.1016/j.dsx.2016.03.009] [PMID: 27016886]
[41]
Rösen, P.; Nawroth, P.P.; King, G.; Möller, W.; Tritschler, H.J.; Packer, L. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab. Res. Rev., 2001, 17(3), 189-212.
[http://dx.doi.org/10.1002/dmrr.196] [PMID: 11424232]
[42]
Pradhan, A.D.; Manson, J.E.; Rifai, N.; Buring, J.E.; Ridker, P.M. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 2001, 286(3), 327-334.
[http://dx.doi.org/10.1001/jama.286.3.327] [PMID: 11466099]
[43]
Bonnefont-Rousselot, D. Glucose and reactive oxygen species. Curr. Opin. Clin. Nutr. Metab. Care, 2002, 5(5), 561-568.
[http://dx.doi.org/10.1097/00075197-200209000-00016] [PMID: 12172481]
[44]
Styskal, J.; Van Remmen, H.; Richardson, A.; Salmon, A.B. Oxidative stress and diabetes: What can we learn about insulin resistance from antioxidant mutant mouse models? Free Radic. Biol. Med., 2012, 52(1), 46-58.
[http://dx.doi.org/10.1016/j.freeradbiomed.2011.10.441] [PMID: 22056908]
[45]
Son, S.M. Reactive oxygen and nitrogen species in pathogenesis of vascular complications of diabetes. Diabetes Metab. J., 2012, 36(3), 190-198.
[http://dx.doi.org/10.4093/dmj.2012.36.3.190] [PMID: 22737658]
[46]
Després, J.P. Abdominal obesity and cardiovascular disease: Is inflammation the missing link? Can. J. Cardiol., 2012, 28(6), 642-652.
[http://dx.doi.org/10.1016/j.cjca.2012.06.004] [PMID: 22889821]
[47]
Schrauwen-Hinderling, V.; Hoeks, J.; Hesselink, M.K. Mitochondrial dysfunction and lipotoxicity. Biochim. Biophys. Acta, 2010, 1801, 266-271.
[48]
Petersen, K.F.; Befroy, D.; Dufour, S.; Dziura, J.; Ariyan, C.; Rothman, D.L.; DiPietro, L.; Cline, G.W.; Shulman, G.I. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science, 2003, 300(5622), 1140-1142.
[http://dx.doi.org/10.1126/science.1082889] [PMID: 12750520]
[49]
Wong-Ekkabut, J.; Xu, Z.; Triampo, W.; Tang, I.M.; Tieleman, D.P.; Monticelli, L. Effect of lipid peroxidation on the properties of lipid bilayers: a molecular dynamics study. Biophys. J., 2007, 93(12), 4225-4236.
[http://dx.doi.org/10.1529/biophysj.107.112565] [PMID: 17766354]
[50]
Soliman, G.Z.A. Blood lipid peroxidation (superoxide dismutase, malondialdehyde, glutathione) levels in Egyptian type 2 diabetic patients. Singapore Med. J., 2008, 49(2), 129-136.
[PMID: 18301840]
[51]
Hung, J.; McQuillan, B.M.; Chapman, C.M.L.; Thompson, P.L.; Beilby, J.P. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler. Thromb. Vasc. Biol., 2005, 25(6), 1268-1273.
[http://dx.doi.org/10.1161/01.ATV.0000163843.70369.12] [PMID: 15790931]
[52]
Drabkin, D.L.; Austin, J.M. Spectrophotometric constants for common hemoglobin derivatives in human, dogand rabbit blood. J. Biol. Chem., 1932, 98, 719-733.
[53]
Yeh, E.T.H.; Willerson, J.T. Coming of age of C-reactive protein: using inflammation markers in cardiology. Circulation, 2003, 107(3), 370-371.
[http://dx.doi.org/10.1161/01.CIR.0000053731.05365.5A] [PMID: 12551854]
[54]
DeFronzo, R.A.; Abdul-Ghani, M. Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose. Am. J. Cardiol., 2011, 108(Suppl. 3), 3B-24B.
[http://dx.doi.org/10.1016/j.amjcard.2011.03.013] [PMID: 21802577]
[55]
Thiyagarajan, R.; Subramanian, S.K.; Sampath, N. Madanmohan Trakroo; Pal, P.; Bobby, Z.; Paneerselvam, S.; Das, A.K. Association between cardiac autonomic function, oxidative stress and inflammatory response in impaired fasting glucose subjects: cross-sectional study. PLoS One, 2012, 7(7) e41889
[http://dx.doi.org/10.1371/journal.pone.0041889] [PMID: 22860025]
[56]
Hartge, M.M.; Unger, T.; Kintscher, U. The endothelium and vascular inflammation in diabetes. Diab. Vasc. Dis. Res., 2007, 4(2), 84-88.
[http://dx.doi.org/10.3132/dvdr.2007.025] [PMID: 17654441]

Rights & Permissions Print Cite
Article Metrics
13
1
© 2024 Bentham Science Publishers | Privacy Policy